ClinicalTrials.gg
CompletedNCT06625814Updated Oct 3, 2024

A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)

A Phase 1 interventional study of Levothyroxine and Enlicitide Decanoate in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

Levothyroxine (T4) is a man-made thyroid hormone used to treat certain thyroid conditions. After taking levothyroxine, a person's body changes it to triiodothyronine (T3). The amount of levothyroxine in a person's blood must be carefully controlled to maintain proper function. Enlicitide decanoate was designed to lower the amount of cholesterol in a person's blood.

Researchers want to learn about levothyroxine when taken at the same time with enlicitide decanoate. They want to:

  • Measure a person's blood to find out if the amount of levothyroxine in the blood is the same when levothyroxine is taken alone or with enlicitide decanoate
  • Learn about the safety of levothyroxine when taken alone or with enlicitide decanoate and if people tolerate it
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Medically healthy with no medical history
  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • History of cardiovascular disease or diabetes mellitus
  • History of cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Levothyroxine

    Participants will receive a single oral dose of levothyroxine.

    Drug: Levothyroxine

  • Experimental
    Levothyroxine Plus Enlicitide Decanoate

    Participants will receive a single oral dose of levothyroxine and a single oral dose of enlicitide decanoate at the same time.

    Drug: Levothyroxine · Drug: Enlicitide Decanoate

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Levothyroxine (total T4)

    Blood samples will be collected to determine the AUC0-48hr of Levothyroxine (T4).

    Time frame: At designated timepoints (up to approximately 48 hours postdose)

  2. Maximum Plasma Concentration (Cmax) of Levothyroxine (total T4)

    Blood samples will be collected to determine the Cmax of Levothyroxine (T4).

    Time frame: At designated timepoints (up to approximately 48 hours postdose)

  3. Time to Maximum Plasma Concentration (Tmax) of Levothyroxine (total T4)

    Blood samples will be collected to determine the Tmax of Levothyroxine (T4).

    Time frame: At designated timepoints (up to approximately 48 hours postdose)

  4. Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Triiodothyronine (total T3)

    Blood samples will be collected to determine the AUC0-48hr of triiodothyronine (T3).

    Time frame: At designated timepoints (up to approximately 48 hours postdose)

  5. Maximum Plasma Concentration (Cmax) of Triiodothyronine (total T3)

    Blood samples will be collected to determine the Cmax of triiodothyronine (T3).

    Time frame: At designated timepoints (up to approximately 48 hours postdose)

  6. Time to Maximum Plasma Concentration (Tmax) of Triiodothyronine (total T3)

    Blood samples will be collected to determine the Tmax of triiodothyronine (T3).

    Time frame: At designated timepoints (up to approximately 48 hours postdose)

Secondary outcomes

  1. Number of Participants Who Experience a Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE will be considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who experience a TEAE will be reported.

    Time frame: Up to approximately 7 weeks

  2. Number of Participants Who Discontinue Study Due to a TEAE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE will be considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who discontinue study due to a TEAE will be reported.

    Time frame: Up to approximately 7 weeks

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Aug 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 3, 2024
StartActual
Jul 8, 2024
Primary completionActual
Aug 19, 2024
CompletionActual
Sep 11, 2024
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625814
Collaborators
Celerion
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Jul 8, 2024
Primary completion
Aug 19, 2024
Completion
Sep 11, 2024
Last update
Oct 3, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Thyroxine · MK-0616

Start the discussion